| 0.6 -0.096 (-13.84%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.51  |
1-year : | 2.02 |
| Resists | First : | 1.29 |
Second : | 1.73 |
| Pivot price | 1.15 |
|||
| Supports | First : | 0.6 |
Second : | 0.49 |
| MAs | MA(5) : | 0.74 |
MA(20) : | 1.21 |
| MA(100) : | 2.56 |
MA(250) : | 2.57 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 3.6 |
D(3) : | 7.2 |
| RSI | RSI(14): 24.1 |
|||
| 52-week | High : | 5.25 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATLN ] has closed above bottom band by 6.2%. Bollinger Bands are 14.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.59 - 0.6 | 0.6 - 0.61 |
Based in Billerica, Massachusetts, and established in 2013, Atlantic International Corp. (which operated as SeqLL Inc. until its name change in June 2024) underwent a significant corporate change on June 18, 2024, when it was acquired by Lyneer Investments, LLC, via a reverse merger. The company operates within the life sciences sector, providing specialized instrumentation and research services. Its primary focus is on generating innovative scientific assets and proprietary intellectual property across various "omics" disciplines. Central to its offerings is the True Single Molecule Sequencing (tSMS) platform. This advanced technology provides a unique single-molecule approach to DNA and RNA sequencing by directly detecting nucleic acids. It empowers researchers to analyze billions of individual molecules within a single experiment, ensuring the generation of highly accurate and reproducible data. Atlantic International's sophisticated solutions cater to diverse applications, including biomarker discovery and the development of diagnostic assays. Its clientele spans academic institutions (such as universities), governmental research centers, and leading companies in the biotechnology and pharmaceutical industries. The company also fosters key collaborations, including an R&D agreement with the U.S. Department of Justice's Federal Bureau of Investigation to assess the forensic potential of direct RNA sequencing using its tSMS platform, and a partnership with the Weizmann Institute of Science to advance and implement cutting-edge single-molecule technologies.
Thu, 11 Jun 2026
Number of shareholders of Atlantic International Corp. – NASDAQ:ATLN - TradingView
Tue, 02 Jun 2026
Atlantic International Corp Receives Notification from Nasdaq Regarding Late Filing of Form 10-Q - The Manila Times
Tue, 02 Jun 2026
Atlantic International receives Nasdaq non-compliance notice - Investing.com
Wed, 08 Apr 2026
ATLN Stock: Atlantic International Corp. Performance Overview - Bitget
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 76 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 72 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 883 (K) |
| Shares Short P.Month | 459 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.58 |
| Profit Margin | -13.7 % |
| Operating Margin | -19.5 % |
| Return on Assets (ttm) | -27 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -7.4 % |
| Gross Profit (p.s.) | 0.6 |
| Sales Per Share | 5.71 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | -0.56 |
| PEG Ratio | 0 |
| Price to Book value | -1.04 |
| Price to Sales | 0.1 |
| Price to Cash Flow | -10.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|